{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T05:51:39Z","timestamp":1791438699670,"version":"4.3.3"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100019675","name":"Centre of Excellence for Biopharmaceutical Technology, Indian Institute of Technology Delhi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019675","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004322","name":"Agilent Technologies Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["BT\/COE\/34\/SP15097\/2015"],"award-info":[{"award-number":["BT\/COE\/34\/SP15097\/2015"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007488","name":"Indian Institute of Technology Delhi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007488","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jchromb.2023.123896","type":"journal-article","created":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T21:32:18Z","timestamp":1695677538000},"page":"123896","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Assessment of structural and functional similarity of biosimilar products: Bevacizumab as a case study"],"prefix":"10.1016","volume":"1229","author":[{"given":"Sanghati","family":"Bhattacharya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5913-4244","authenticated-orcid":false,"given":"Anurag S.","family":"Rathore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2023.123896_b0005","first-page":"479","article-title":"Biosimila\u2014s-new horizon of the generic drugs","volume":"6","author":"Das","year":"2018","journal-title":"Int. J. Pharm. Drug Anal."},{"key":"10.1016\/j.jchromb.2023.123896_b0010","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3390\/biom9090410","article-title":"The breakthrough of biosimilars: A twist in the narrative of biological therapy","volume":"9","author":"Kabir","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.jchromb.2023.123896_b0015","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40942-021-00343-3","article-title":"Future of anti-VEGF: biosimilars and biobetters","volume":"8","author":"Kapur","year":"2022","journal-title":"Int. J. Retina Vitreous"},{"key":"10.1016\/j.jchromb.2023.123896_b0020","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/10826068.2021.1959346","article-title":"Regulatory considerations in biosimilars: Middle East and Africa regions","volume":"51","author":"Rathore","year":"2021","journal-title":"Prep. Biochem. Biotech."},{"key":"10.1016\/j.jchromb.2023.123896_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10826068.2020.1815061","article-title":"Regulatory considerations in biosimilars: Asia pacific regions","volume":"51","author":"Rathore","year":"2021","journal-title":"Prep. Biochem. Biotech."},{"key":"10.1016\/j.jchromb.2023.123896_b0030","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/10826068.2021.1876729","article-title":"Regulatory considerations in biosimilars: Latin America region","volume":"51","author":"Rathore","year":"2021","journal-title":"Prep. Biochem. Biotech."},{"key":"10.1016\/j.jchromb.2023.123896_b0035","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.xphs.2021.11.024","article-title":"Oxidation and deamidation of monoclonal antibody products: potential impact on stability, biological activity, and efficacy","volume":"111","author":"Gupta","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jchromb.2023.123896_b0040","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jchromb.2018.07.037","article-title":"Rapid charge variant analysis of monoclonal antibodies to support lead candidate biopharmaceutical development","volume":"1095","author":"Trappe","year":"2018","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2023.123896_b0045","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jchromb.2017.05.010","article-title":"Protocols for the analytical characterization of therapeutic monoclonal antibodies. I \u2013 Non-denaturing chromatographic techniques","volume":"1058","author":"Goyon","year":"2017","journal-title":"J. Chromatogr. B."},{"key":"10.1016\/j.jchromb.2023.123896_b0050","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.832059","article-title":"Analytical similarity assessment of biosimilars: global regulatory landscape, recent studies and major advancements in orthogonal platforms","volume":"10","author":"Nupur","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.jchromb.2023.123896_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchromb.2019.05.014","article-title":"Insights from capillary electrophoresis approaches for characterization of monoclonal antibodies and antibody drug conjugates in the period 2016\u20132018","volume":"1122\u20131123","author":"Lechner","year":"2019","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2023.123896_b0060","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jchromb.2017.09.033","article-title":"Determination of isoelectric points and relative charge variants of 23 therapeutic monoclonal antibodies","volume":"1065\u20131066","author":"Goyon","year":"2017","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2023.123896_b0065","doi-asserted-by":"crossref","first-page":"e0208354","DOI":"10.1371\/journal.pone.0208354","article-title":"An evaluation roadmap for critical quality attributes from tier 1 in analytical similarity assessment","volume":"13","author":"Wu","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jchromb.2023.123896_b0070","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/14712598.2021.1973426","article-title":"Analytical similarity assessment of MYL-1402O to reference Bevacizumab","volume":"22","author":"Goyal","year":"2022","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.jchromb.2023.123896_b0075","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.dmpk.2018.11.004","article-title":"Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies","volume":"34","author":"Ishii-Watabe","year":"2019","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.jchromb.2023.123896_b0080","unstructured":"Analytical Similarity of a Proposed Biosimilar BVZ-BC to Bevacizumab | Analytical Chemistry, (n.d.). https:\/\/pubs.acs.org\/doi\/full\/10.1021\/acs.analchem.9b04871 (accessed April 29, 2023)."},{"key":"10.1016\/j.jchromb.2023.123896_b0085","unstructured":"Full article: Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab, (n.d.). https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/19420862.2018.1452580 (accessed April 29, 2023)."},{"key":"10.1016\/j.jchromb.2023.123896_b0090","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/dta.2609","article-title":"Rapid characterization of structural and functional similarity for a candidate bevacizumab (Avastin) biosimilar using a multipronged mass-spectrometry-based approach","volume":"11","author":"Brown","year":"2019","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.jchromb.2023.123896_b0095","doi-asserted-by":"crossref","first-page":"W315","DOI":"10.1093\/nar\/gky497","article-title":"BeStSel: a web server for accurate protein secondary structure prediction and fold recognition from the circular dichroism spectra","volume":"46","author":"Micsonai","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jchromb.2023.123896_b0100","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijbiomac.2022.12.011","article-title":"Taking the individual bias out of examining comparability of biosimilars: A case study on monoclonal antibody therapeutics","volume":"227","author":"Rathore","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jchromb.2023.123896_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115527","article-title":"A novel filter-assisted protein precipitation (FAPP) based sample pre-treatment method for LC-MS peptide mapping for biosimilar characterization","volume":"234","author":"Bhattacharya","year":"2023","journal-title":"J. Pharmaceut. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2023.123896_b0110","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.electacta.2016.04.097","article-title":"Bevacizumab anticancer monoclonal antibody: native and denatured redox behaviour","volume":"206","author":"Issaad","year":"2016","journal-title":"Electrochim. Acta"},{"key":"10.1016\/j.jchromb.2023.123896_b0115","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/glycob\/cwr027","article-title":"High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans","volume":"21","author":"Goetze","year":"2011","journal-title":"Glycobiology"},{"key":"10.1016\/j.jchromb.2023.123896_b0120","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ab.2018.06.003","article-title":"Secondary structure assessment of formulated bevacizumab in the presence of SDS by deep ultraviolet resonance Raman (DUVRR) spectroscopy","volume":"555","author":"Qiu","year":"2018","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.jchromb.2023.123896_b0125","unstructured":"High-Throughput Thermal Stability Analysis of a Monoclonal Antibody by Attenuated Total Reflection FT-IR Spectroscopic Imaging | Analytical Chemistry, (n.d.). https:\/\/pubs.acs.org\/doi\/full\/10.1021\/ac502529q (accessed April 29, 2023)."},{"key":"10.1016\/j.jchromb.2023.123896_b0130","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nprot.2015.024","article-title":"Obtaining information about protein secondary structures in aqueous solution using Fourier transform IR spectroscopy","volume":"10","author":"Yang","year":"2015","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.jchromb.2023.123896_b0135","first-page":"349","article-title":"The use of circular dichroism in the investigation of protein structure and function, current protein and peptide","volume":"1","author":"Kelly","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.jchromb.2023.123896_b0140","doi-asserted-by":"crossref","first-page":"e0215442","DOI":"10.1371\/journal.pone.0215442","article-title":"Conformational characterization of a novel anti-HER2 candidate antibody","volume":"14","author":"P\u00e9rez","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jchromb.2023.123896_b0145","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01079","article-title":"Quality, non-clinical and clinical considerations for biosimilar monoclonal antibody development: EU, WHO, USA, Canada, and BRICS-TM regulatory guidelines","volume":"9","author":"Rahalkar","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jchromb.2023.123896_b0150","first-page":"369","article-title":"Characterization of bevacizumab by dynamic light scattering while maintaining its native structure","volume":"73","author":"Akbas","year":"2018","journal-title":"Die Pharmazie \u2013 Int. J. Pharmaceut. Sci."},{"key":"10.1016\/j.jchromb.2023.123896_b0155","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1021\/acs.jpcb.1c10528","article-title":"High-pressure, low-temperature induced unfolding and aggregation of monoclonal antibodies: role of the fc and fab fragments","volume":"126","author":"Berger","year":"2022","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.jchromb.2023.123896_b0160","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3390\/pharmaceutics14081571","article-title":"Structural and functional analysis of CEX fractions collected from a novel Avastin\u00ae biosimilar candidate and Its innovator: A comparative study","volume":"14","author":"Gurel","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jchromb.2023.123896_b0165","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3390\/bioengineering9110641","article-title":"Challenges and strategies for a thorough characterization of antibody acidic charge variants","volume":"9","author":"Liu","year":"2022","journal-title":"Bioengineering"},{"key":"10.1016\/j.jchromb.2023.123896_b0170","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1038\/s41598-020-79541-2","article-title":"LC\u2013MS based case-by-case analysis of the impact of acidic and basic charge variants of bevacizumab on stability and biological activity","volume":"11","author":"Singh","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jchromb.2023.123896_b0175","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/19420862.2017.1402996","article-title":"Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study","volume":"10","author":"Nupur","year":"2018","journal-title":"MAbs"},{"key":"10.1016\/j.jchromb.2023.123896_b0180","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.xphs.2021.09.006","article-title":"Characterization of N-terminal glutamate cyclization in monoclonal antibody and bispecific antibody using charge heterogeneity assays and hydrophobic interaction chromatography","volume":"111","author":"Cao","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jchromb.2023.123896_b0185","article-title":"Review on monoclonal antibodies\u2013Manufacturing aspects, tactics, and future prospects","volume":"16","author":"Nithya","year":"2022","journal-title":"Int. J. Green Pharma. (IJGP)"},{"key":"10.1016\/j.jchromb.2023.123896_b0190","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.18553\/jmcp.2021.27.8.1129","article-title":"Overcoming barriers to biosimilar adoption: real-world perspectives from a national payer and provider initiative","volume":"27","author":"Edgar","year":"2021","journal-title":"JMCP"},{"key":"10.1016\/j.jchromb.2023.123896_b0195","first-page":"2169","article-title":"On assessment of analytical similarity in biosimilar studies","volume":"3","author":"Chow","year":"2014","journal-title":"Drug Des."},{"key":"10.1016\/j.jchromb.2023.123896_b0200","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/19420862.2018.1440170","article-title":"Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses","volume":"10","author":"Lee","year":"2018","journal-title":"MAbs"},{"key":"10.1016\/j.jchromb.2023.123896_b0205","unstructured":"U. CDER, Quality review BLA761042-GP2015 (Etanercept), Sandoz. 2016. Application number 761042Orig1s000 chemistry review (s), 2018."},{"key":"10.1016\/j.jchromb.2023.123896_b0210","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1208\/s12248-020-00454-z","article-title":"Quality by design-based assessment for analytical similarity of adalimumab biosimilar HLX03 to Humira\u00ae","volume":"22","author":"Zhang","year":"2020","journal-title":"AAPS J."},{"key":"10.1016\/j.jchromb.2023.123896_b0215","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.biologicals.2017.04.005","article-title":"Considerations of critical quality attributes in the analytical comparability assessment of biosimilar products","volume":"48","author":"Kwon","year":"2017","journal-title":"Biologicals"},{"key":"10.1016\/j.jchromb.2023.123896_b0220","unstructured":"Multi-fingerprint profiling combined with chemometric methods for investigating the quality of Astragalus polysaccharides - ScienceDirect, (n.d.). https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0141813018335682 (accessed April 29, 2023)."},{"key":"10.1016\/j.jchromb.2023.123896_b0225","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jchromb.2016.05.027","article-title":"Assessing analytical comparability of biosimilars: GCSF as a case study","volume":"1032","author":"Nupur","year":"2016","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2023.123896_b0230","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40259-020-00404-3","article-title":"Assessment of structural and functional comparability of biosimilar products: Trastuzumab as a case study","volume":"34","author":"Joshi","year":"2020","journal-title":"BioDrugs"},{"key":"10.1016\/j.jchromb.2023.123896_b0235","doi-asserted-by":"crossref","first-page":"258","DOI":"10.56530\/lcgc.na.xe1872r3","article-title":"Establishing analytical and functional comparability for biosimilars","volume":"40","author":"Rathore","year":"2022","journal-title":"LCGC N. Am."},{"key":"10.1016\/j.jchromb.2023.123896_b0240","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1002\/jctb.5636","article-title":"Enhanced product understanding in the QbD paradigm: linkage between charge heterogeneity and stability of monoclonal antibody therapeutic products","volume":"93","author":"Joshi","year":"2018","journal-title":"J. Chem. Technol. Biotechnol."},{"key":"10.1016\/j.jchromb.2023.123896_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122646","article-title":"Physicochemical characterization and functionality comparison of Humira\u00ae(adalimumab), Remicade\u00ae(infliximab) and Simponi Aria\u00ae(golimumab)","volume":"635","author":"Kinzer","year":"2023","journal-title":"Int. J. Pharm."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023223003069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023223003069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T23:14:26Z","timestamp":1761606866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023223003069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":49,"alternative-id":["S1570023223003069"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2023.123896","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of structural and functional similarity of biosimilar products: Bevacizumab as a case study","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2023.123896","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"123896"}}